First Patient Dosed in Phase 2 Trial of eFT508 for Aggressive Non-Hodgkin’s Lymphoma
News
The Phase 1/2 clinical trial evaluating eFT508 for the treatment of relapsed or refractory non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL) has dosed the first patient in its Phase ... Read more